Blurbs

Agile Therapeutics (AGRX) Gets a Buy from Maxim Group

In a report released on November 8, Naz Rahman from Maxim Group maintained a Buy rating on Agile Therapeutics (AGRXResearch Report), with a price target of $1.00. The company’s shares closed yesterday at $0.20.

According to TipRanks, Rahman is an analyst with an average return of -38.3% and a 16.88% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, 9 Meters Biopharma, and Clene.

Currently, the analyst consensus on Agile Therapeutics is a Moderate Buy with an average price target of $3.00.

See today’s best-performing stocks on TipRanks >>

Based on Agile Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.13 million and a GAAP net loss of $12.22 million. In comparison, last year the company earned a revenue of $1.19 million and had a GAAP net loss of $17.64 million

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Read More on AGRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More